» Articles » PMID: 38895368

Chemical Signatures Delineate Heterogeneous Amyloid Plaque Populations Across the Alzheimer's Disease Spectrum

Abstract

Amyloid plaque deposition is recognized as the primary pathological hallmark of Alzheimer's disease(AD) that precedes other pathological events and cognitive symptoms. Plaque pathology represents itself with an immense polymorphic variety comprising plaques with different stages of amyloid fibrillization ranging from diffuse to fibrillar, mature plaques. The association of polymorphic Aβ plaque pathology with AD pathogenesis, clinical symptoms and disease progression remains unclear. Advanced chemical imaging tools, such as functional amyloid microscopy combined with MALDI mass spectrometry imaging (MSI), are now enhanced by deep learning algorithms. This integration allows for precise delineation of polymorphic plaque structures and detailed identification of their associated Aβ compositions. We here set out to make use of these tools to interrogate heterogenic plaque types and their associated biochemical architecture. Our findings reveal distinct Aβ signatures that differentiate diffuse plaques from fibrilized ones, with the latter showing substantially higher levels of Aβx-40. Notably, within the fibrilized category, we identified a distinct subtype known as coarse-grain plaques. Both in sAD and fAD brain tissue, coarse grain plaques contained more Aβx-40 and less Aβx-42 compared with cored plaques. The coarse grain plaques in both sAD and fAD also showed higher levels of neuritic content including paired helical filaments (PHF-1)/phosphorylated phospho Tau-immunopositive neurites. Finally, the Aβ peptide content in coarse grain plaques resembled that of vascular Aβ deposits (CAA) though with relatively higher levels of Aβ1-42 and pyroglutamated Aβx-40 and Aβx-42 species in coarse grain plaques. This is the first of its kind study on spatial biochemical characterization of different plaque morphotypes demonstrating the potential of the correlative imaging techniques used that further increase the understanding of heterogeneous AD pathology. Linking the biochemical characteristics of amyloid plaque polymorphisms with various AD etiologies and toxicity mechanisms is crucial. Understanding the connection between plaque structure and disease pathogenesis can enhance our insights. This knowledge is particularly valuable for developing and advancing novel, amyloid-targeting therapeutics.

References
1.
Thal D, Walter J, Saido T, Fandrich M . Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer's disease. Acta Neuropathol. 2014; 129(2):167-82. DOI: 10.1007/s00401-014-1375-y. View

2.
Satlin A, Wang J, Logovinsky V, Berry S, Swanson C, Dhadda S . Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease. Alzheimers Dement (N Y). 2017; 2(1):1-12. PMC: 5644271. DOI: 10.1016/j.trci.2016.01.001. View

3.
Nystrom S, Psonka-Antonczyk K, Ellingsen P, Johansson L, Reitan N, Handrick S . Evidence for age-dependent in vivo conformational rearrangement within Aβ amyloid deposits. ACS Chem Biol. 2013; 8(6):1128-33. DOI: 10.1021/cb4000376. View

4.
Hayato S, Takenaka O, Sreerama Reddy S, Landry I, Reyderman L, Koyama A . Population pharmacokinetic-pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease. CPT Pharmacometrics Syst Pharmacol. 2022; 11(12):1578-1591. PMC: 9755918. DOI: 10.1002/psp4.12862. View

5.
Nystrom S, Back M, Nilsson K, Hammarstrom P . Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging. J Vis Exp. 2017; (128). PMC: 5755170. DOI: 10.3791/56279. View